AMPLIFAI: A Multiphase CT Dataset for Benchmarking Clinical Reasoning in LI-RADS Assessment of Liver Lesions

Early diagnosis of hepatocellular carcinoma is critical to preserve access to curative treatment options. The Liver Imaging Reporting and Data System (LI-RADS) provides a standardized framework for non-invasive diagnosis on multiphase computed tomography, based on major visual imaging features. However, these features may be difficult to assess consistently, particularly in small liver lesions. We developed dLI-RADS, an interpretable artificial intelligence method designed to estimate the probability of hepatocellular carcinoma from multiphase computed tomography images of manually segmented liver lesions, while remaining aligned with LI-RADS-related imaging concepts. dLI-RADS combines neural network-derived predictions with handcrafted quantitative imaging measurements reflecting LI-RADS major features and integrates these inputs using logistic regression. In this multicenter retrospective study, patients with multiphase computed tomography and at least one liver lesion were included, while lesions larger than 40 mm were excluded. Histology served as the reference standard for hepatocellular carcinoma, and a composite reference standard was used for non-hepatocellular carcinoma lesions. The lesion-level accuracy of dLI-RADS and LI-RADS were compared on the internal evaluation set using 10,000-repetition bootstrap non-inferiority tests, with 5% margins and significance levels. On the external test set, sensitivities were similarly compared. dLI-RADS was non-inferior to LI-RADS for lesion-level accuracy in the internal evaluation set, achieving 80% accuracy compared with 74% for LI-RADS (p = 0.04)...

Liver cancer is a complex disease responsible for a high number of deaths across the globe each year, making automated solutions for liver cancer classification urgent. The most common form of liver cancer is hepatocellular carcinoma (HCC), accounting for over 90% of liver cancer cases. There is a distinct lack of publicly available HCC datasets utilizing genomic data, which is necessary for training artificial intelligence (AI) models for automated HCC classification. This study proposes constructing a multi-stage HCC dataset using XGBoost and Semi-Supervised learning on three separate datasets of genomic biomarkers, utilizing their existing labels in the Semi-Supervised learning process to label the proposed dataset. The proposed dataset consists of 770 patient samples in total, categorized into five classes that represent normal tissue alongside different stages of HCC. Each sample in the dataset consists of 11,150 different gene expression levels. The XGBoost model demonstrated a final classification accuracy of 96.5% during the Semi-Supervised learning process.

Artificial intelligence (AI) can automatically delineate lesions on computed tomography (CT) and generate radiology report content, yet progress is limited by the scarcity of publicly available CT datasets with lesion-level annotations. To bridge this gap, we introduce CT-Bench, a first-of-its-kind benchmark dataset comprising two components: a Lesion Image and Metadata Set containing 20,335 lesions from 7,795 CT studies with bounding boxes, descriptions, and size information, and a multitask visual question answering benchmark with 2,850 QA pairs covering lesion localization, description, size estimation, and attribute categorization. Hard negative examples are included to reflect real-world diagnostic challenges. We evaluate multiple state-of-the-art multimodal models, including vision-language and medical CLIP variants, by comparing their performance to radiologist assessments, demonstrating the value of CT-Bench as a comprehensive benchmark for lesion analysis. Moreover, fine-tuning models on the Lesion Image and Metadata Set yields significant performance gains across both components, underscoring the clinical utility of CT-Bench.